Ebola is now a threat of global significance. Fatalities are a consequence of the human body's overreactive responses to the virus. These responses are largely driven by molecules on cells called integrins. In collaboration with Professor Thomas Geisbert, co-discoverer of Ebola-Reston, we will test the hypothesis that our experimental anti-integrin drug OS2966 improves survival in a primate model of Ebola Virus Disease. If successful, we will pursue clinical trials in patients.